TUHURA BIOSCIENCES INC (HURA) Stock Price, Quote, News and Overview
NASDAQ:HURA - Nasdaq - US8989201038 - Common Stock - Currency: USD
HURA Quote, Performance and Key Statistics
2.83
-0.18 (-5.98%)
The current stock price of HURA is 2.83 USD. In the past month the price decreased by -30.98%.
HURA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.84 | 324.18B | ||
| AMGN | AMGEN INC | 13.09 | 146.06B | ||
| GILD | GILEAD SCIENCES INC | 13.87 | 133.68B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 112.09B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.28 | 63.52B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 37.72B | ||
| ARGX | ARGENX SE - ADR | 100.1 | 35.88B | ||
| ONC | BEIGENE LTD-ADR | 6 | 26.02B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.72B | ||
| NTRA | NATERA INC | N/A | 20.84B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.20B | ||
| BIIB | BIOGEN INC | 7.95 | 18.43B |
Related stock screener links
About HURA
Company Profile
TuHURA Biosciences, Inc. is a phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company is headquartered in Tampa, Florida and currently employs 19 full-time employees. The company went IPO on 2016-07-12. The Company’s lead personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company is preparing to initiate a single randomized placebo-controlled Phase III registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first line treatment for advanced Merkel cell carcinoma. In addition, the Company is leveraging its Delta receptor technology to develop novel bi-functional antibody drug conjugates (ADCs), targeting myeloid derived suppressor cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies. Its IFx platform technology utilizes a proprietary plasmid DNA (pDNA) or messenger RNA (mRNA).
Company Info
TUHURA BIOSCIENCES INC
10500 University Center Dr., Suite 110
Tampa FLORIDA US
Employees: 19
Phone: 18138756600
TUHURA BIOSCIENCES INC / HURA FAQ
What is the stock price of TUHURA BIOSCIENCES INC today?
The current stock price of HURA is 2.83 USD. The price decreased by -5.98% in the last trading session.
What is the ticker symbol for TUHURA BIOSCIENCES INC stock?
The exchange symbol of TUHURA BIOSCIENCES INC is HURA and it is listed on the Nasdaq exchange.
On which exchange is HURA stock listed?
HURA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for TUHURA BIOSCIENCES INC stock?
7 analysts have analysed HURA and the average price target is 15.3 USD. This implies a price increase of 440.64% is expected in the next year compared to the current price of 2.83. Check the TUHURA BIOSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is TUHURA BIOSCIENCES INC worth?
TUHURA BIOSCIENCES INC (HURA) has a market capitalization of 123.61M USD. This makes HURA a Micro Cap stock.
How many employees does TUHURA BIOSCIENCES INC have?
TUHURA BIOSCIENCES INC (HURA) currently has 19 employees.
What are the support and resistance levels for TUHURA BIOSCIENCES INC (HURA) stock?
TUHURA BIOSCIENCES INC (HURA) has a resistance level at 3.62. Check the full technical report for a detailed analysis of HURA support and resistance levels.
Should I buy TUHURA BIOSCIENCES INC (HURA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of HURA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of HURA, evaluating the profitability, health, valuation and growth aspects
- TUHURA BIOSCIENCES INC (HURA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- TUHURA BIOSCIENCES INC (HURA) Sales and EPS estimates to see what analysts future expectations are.
- TUHURA BIOSCIENCES INC (HURA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- TUHURA BIOSCIENCES INC (HURA) Insider and Institutional Ownership to learn about the owners and their transactions.
- TUHURA BIOSCIENCES INC (HURA) Stock Chart to make your own analysis
- TUHURA BIOSCIENCES INC (HURA) Latest news and press-releases to stay up to date.
Does TUHURA BIOSCIENCES INC (HURA) stock pay dividends?
HURA does not pay a dividend.
When does TUHURA BIOSCIENCES INC (HURA) report earnings?
TUHURA BIOSCIENCES INC (HURA) will report earnings on 2025-10-06, after the market close.
What is the Price/Earnings (PE) ratio of TUHURA BIOSCIENCES INC (HURA)?
TUHURA BIOSCIENCES INC (HURA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-5.32).
What is the Short Interest ratio of TUHURA BIOSCIENCES INC (HURA) stock?
The outstanding short interest for TUHURA BIOSCIENCES INC (HURA) is 7.47% of its float. Check the ownership tab for more information on the HURA short interest.
HURA Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to HURA.
HURA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to HURA. While HURA seems to be doing ok healthwise, there are quite some concerns on its profitability.
HURA Financial Highlights
Over the last trailing twelve months HURA reported a non-GAAP Earnings per Share(EPS) of -5.32. The EPS increased by 5.32% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -655.84% | ||
| ROE | -1601.86% | ||
| Debt/Equity | 0 |
HURA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to HURA. The Buy consensus is the average rating of analysts ratings from 7 analysts.